AcelRx Pharmaceuticals Rebrands to Talphera, Expands Therapeutic Focus
AcelRx Pharmaceuticals, a specialty pharmaceutical company, has announced its rebranding to Talphera, Inc. The decision to rebrand comes as the company seeks to expand its therapeutic focus beyond acute pain management in medically supervised settings. The shift in strategic direction underscores the company’s commitment to advancing care and developing innovative therapies.
Talphera to Begin Trading on Nasdaq with Ticker Symbol “TLPH“
As part of its rebranding efforts, Talphera will start trading on the Nasdaq Global Market under the new ticker symbol “TLPH” starting Wednesday, January 10, 2024. This change reflects the company’s transformation and highlights its new direction in the pharmaceutical industry. With the new ticker symbol, Talphera aims to establish itself as a leading player in the market.
Niyad Anticoagulant Receives FDA Breakthrough Designation
Talphera’s lead product candidate, Niyad, has been granted FDA Breakthrough Designation. Niyad is being studied as an anticoagulant for extracorporeal circuits, showcasing its potential to address critical medical needs in patients undergoing renal replacement therapy. This designation recognizes the significant potential of Niyad in providing effective and safer anticoagulation therapy options.
Talphera’s NEPHRO CRRT Study Receives IRB Approval
Talphera’s NEPHRO CRRT Study, a Phase 3 trial for Niyad, has received Institutional Review Board (IRB) approval. This important milestone paves the way for the enrollment of the first patient in the trial. The NEPHRO CRRT Study aims to evaluate the effectiveness of Niyad in patients undergoing renal replacement therapy who are unable to tolerate heparin or are at risk for bleeding. This study holds promise for patients who require alternative anticoagulation options.
Talphera’s Transformation Reflects Leadership in New Pharmaceutical Era
The rebranding of AcelRx Pharmaceuticals to Talphera is presented as a strategic evolution, marking a new era for the company’s mission and focus. The new name, derived from “Talisman,” symbolizes leadership and signifies the company’s commitment to driving innovation and advancements in the pharmaceutical industry. With its expanded therapeutic focus and innovative product candidates, Talphera is poised to make a significant impact on patient care in medically supervised settings.
The information in this article is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information, see our T&C.
Analyst comment
Positive news. Talphera (formerly AcelRx Pharmaceuticals) is rebranding and expanding its therapeutic focus. The company will begin trading on Nasdaq and has received FDA Breakthrough Designation for its lead product candidate, Niyad. The NEPHRO CRRT Study has also received IRB approval. Talphera’s transformation reflects its commitment to innovation and patient care. Market response is expected to be positive, as the company diversifies its offerings and demonstrates significant potential in the pharmaceutical industry.
